Attovia Therapeutics raised about $289 million in an upsized IPO to fund clinical development across its immunology and inflammation pipeline. The offering priced 17 million shares at $17 each, extending an unusually active IPO window for drugmakers targeting inflammatory markets. Management positioned the proceeds as runway for upcoming clinical milestones into 2027, with investors focusing on the platform’s ability to differentiate against incumbents in itch and broader immune-driven indications. The IPO timing also aligns with the market’s appetite for immunology assets that can reach registrational endpoints on a defined timeline. For the sector, Attovia’s launch is another data point that public-market access is increasingly available for earlier development-stage biotechs with clear clinical catalysts and credible funding narratives.